Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our albumin-based drug enhancing technologies. We partner with excellence to improve therapies for people with serious diseases. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. Headquartered in Nottingham, England with more than 80 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.
Dr Phil MortonChief Technology Officer
Jonas Skjødt MøllerChief Operating Officer
Dr Joanna HayAccount Director, Europe
Arcinova is a UK based Contract Research and Development Organisation (CRDO) operating from a 15,000msq site which has benefited from more than 36 years of investment as a key research and development centre. We provide the pharmaceutical industry with a comprehensive range of services, backed by extensive scientific expertise and strong practical capabilities. We work to enhance the health and wellbeing of society by helping companies to develop life changing medicines and take them to market quickly, effectively and efficiently.
Our focus is on API process research, the development, validation and application of analytical, microbiological and materials science spectroscopic methodologies, scale-up and early phase clinical product manufacturing. We provide non-clinical and clinical 14C, API, drug product, bioanalysis, regulatory and consulting services.
Our mission at Arcinova is to delight our life sciences customers by satisfying their contract research, development and manufacturing needs with agility, innovation, seamless teamwork and best value delivery.
Dr Nathalie HutherBusiness Development Manager Europe
Bionow supports business growth, competitiveness and innovation within the biomedical and life science sectors across Northern England. Our membership services add value and cost-efficiency to scientific, clinical and business operations within early stage and growth-oriented firms. Simply put, we are here to help you grow your business.
Diane QuinnEvents manager
Exhibiting with the UK delegation at booth 5a
BioPartner UK leads the UK Delegation to several partnering conferences each year, and is your contact at BIO-Europe Spring. It is a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.
BioPartner has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.
Lin BatesonChief Executive
Della Bateson-ChaffeOperations manager
William WatsonBoard member
Clinical Network Services (UK) Ltd
Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA. CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.
CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team. BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.
With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies. CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle.
Dimity GransburySenior Business Development Manager
Fusion Antibodies plc
Fusion Antibodies is a high quality European CRO that offers a range of fee-for-service, royalty free services covering all stages of preclinical therapeutic and diagnostic antibody development.We want to use our next generation CDRx Antibody Humanization Platform to partner with companies interested in developing high quality antibody leads.
We also offer a range of cell line development services and have the associated expertise and partners to deliver a high quality CHO cell line expression for your protein of interest from proof-of-concept to cGMP. Fusion Antibodies also specialize in high quality monoclonal antibodies (particularly those which are difficult to produce), Antibody Sequencing and other Antibody engineering project (scFv, F(ab), chimerics etc). We have the capacity to act as a 1-stop shop, guiding your project from discovery to validation to the clinic.
Dr Julie GormleyDirector of Business Development
Dr Paul KerrCEO
Healx is a Cambridge biotechnology company using its proprietary AI discovery platform to identify new treatment options for rare diseases. Healx has built a pipeline of rare diseases assets and has set an ambitious goal to create 100 new therapeutic opportunities for rare diseases to 2025. Our leading programme in Fragile X is currently phase 2a ready. Other assets are in pre-clinical phase such as Pitt Hopkins and CDKL5.
Healx also partners with pharma companies and charities to help them build rare diseases portfolios faster.
Dr Michale Bouskila-ChubbHead of Business Development
ImmuPharma PLC is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM). The company is focusing on developing novel medicines for specialist indications with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and over 70 patents. Forigerimod (P140 or Lupuzor™) is the company’s most advanced drug candidate for autoimmune diseases and is an immunomodulator, not an immunosuppressant. Lupuzor ™ received "Fast Track" designation from the US FDA and has recently completed a Phase III trial.
Forigerimod is a first-in-class peptide drug modulating autophagy.
ImmuPharma is based in London, U.K. and has three subsidiaries in France and one in Switzerland.
Dimitri DimitriouChief Executive Officer
Karma Oncology Ltd
Karma Oncology is a specialized oncology clinical development organisation headquartered in Scotland with offices in Ireland, Netherlands and USA.
Karma offers a bespoke service, from the preparation of clinical development plans through design, set-up & execution of clinical trials. Our expertise includes the design and execution of autologous and CAR-T cell therapy studies in Europe and North America.
The company was founded in 2012 by Dr Karen J Williams, who, while working as a Sponsor, had become increasingly frustrated by the inevitable constraints and rigidity smaller companies can experience being lost and forgotten in larger CRO’s. Utilizing her 30 years’ experience in pharma and CRO industries, Dr Williams started Karma Oncology to ensure smaller biotech’s get the service and attention they deserve. She has surrounded herself with like-minded professionals and built a team, who, like herself have a passion for this work and are nowledgeable, Adaptable, Reliable, Motivated and Accountable.
Dr Karen WilliamsCEO
MediWales is the life science network for Wales, a not-for-profit, independent company that creates business opportunities and partnerships for our members. We support 180 members from the medical technology, diagnostic and pharmaceutical industries, NHS health boards, university departments and professional services and suppliers.
We create collaboration through our popular programme of events that focus on strategic issues for the life science industry, including regulatory updates, market access, finance and funding, clinical unmet needs and international trade. Throughout the year we host a range of Special Interest Groups focusing on Medical Technology & Diagnostics, BioPharma and Natural Compounds.